A class action complaint filed last week in New Jersey federal court claims damages for violations of the Sherman Antitrust Act by brand-name and generic manufacturers of the drug, Androgel.
The suit alleges that brand name and generic manufacturers conspired to fix and raise the price of Androgel, by overcharging Plaintiffs and others by millions of dollars and depriving them of cheaper generic versions of the drug. The complaint estimates that hundreds or thousands of people or companies have been economically injured by the drug manufacturers' conduct.
Androgel is a testosterone replacement therapy for men who have a deficiency or absence of endogenous testosterone.
The case, filed by Stephen L. LaFrance Pharmacy, Inc. d/b/a SAJ Distributors and Stephen L. LaFrance Holdings, Inc., names as Defendants Unimed Pharmaceuticals Inc., Solvay Pharmaceuticals Inc., Watson Pharmaceuticals Inc., Par Pharmaceuticals, Inc. and Paddock Laboratories, Inc.
The lawsuit is filed on behalf of all persons or entities that purchased Androgel directly from any defendant from at least January 1, 2006 until a date yet to be determined.